Financial Results<\/b><\/p>\n
Revenue<\/i><\/b><\/p>\n
\nConsolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022. The revenues for the third quarter of fiscal 2023 consisted of $7.86 million in processing and storage fees, $3,000 in product revenue and $4,000 in public banking revenue compared to $7.52 million in processing and storage fees, $21,000 in product revenue and $138,000 in public banking revenue for the third quarter of fiscal 2022.<\/p>\n
Net Income<\/i><\/b><\/p>\n
\nThe Company reported net income for the three months ended August 31, 2023 of $681,000, or $0.08 per basic share and diluted share, compared to net income of $467,000, or $0.06 per basic and diluted share for the three months ended August 31, 2022. During the three months ended August 31, 2023, revenue increased 2%, cost of sales decreased 8% and selling, general and administration expenses increased 6%. For the three months ended August 31, 2023, the Company recorded $344,000 in research, development and relating engineering (\u201cR&D\u201d) expenses versus $80,000 for the three months ended August 31, 2022. The increase in R&D expenses as of the three months ended August 31, 2023 versus the same period in 2022 is due to the Clinical Study and Research Agreement the Company entered into with Duke to provide funding to complete the Duke IMPACT Study (as previously disclosed) and the expenses related to the development of a manufacturing laboratory related to the Duke License Agreement. During the second quarter of fiscal 2023, the Company entered into an interest rate SWAP agreement to manage exposure to interest rate risk related to its variable debt obligation under its Term Note (as previously disclosed). For the three months ended August 31, 2023 the Company recorded a gain on the change in the fair value of the derivative of $283,000. The fair value is based on prevailing market data and derived from proprietary models based on well recognized financial principles and reasonable estimates about relevant future market conditions.<\/p>\n
Commentary<\/b><\/p>\n
\nDavid Portnoy, Chairman of the Board and Co-CEO, commented, \u201cWe remain focused on driving forward the potential clinical use of cord blood and cord tissue cells to treat a variety of neurological indications, including cerebral palsy, autism, and hypoxic ischemic encephalopathy. We are currently funding the completion of a Phase 2 autism trial and expect to begin a Phase 3 CP trial in the first half of 2024. These clinical trials and the R&D investments associated with a commercial grade, stem cell laboratory are currently anticipated to be the major use of the Company\u2019s cash flows over the next several years.\u201d<\/p>\n
About Cryo-Cell International, Inc.<\/i><\/b><\/p>\n
\nFounded in 1989, Cryo-Cell International, Inc. is the world\u2019s first private cord blood bank. \u200eMore than 500,000 parents from 87 countries have entrusted Cryo-Cell International with \u200etheir baby\u2019s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell \u200eInternational has a public banking program in partnership with Duke University. Cryo-Cell\u2019s \u200epublic bank has provided cord blood for more than 600 transplantations and operates cord \u200eblood donation sites across the U.S in prominent hospitals such as Cedars\u2013Sinai Hospital in \u200eLos Angeles and Baptist Hospital in Miami. Cryo-Cell\u2019s facility is FDA registered, cGMP-\/cGTP-\u200ecompliant and licensed in all states requiring licensure. Besides being AABB accredited as a \u200ecord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to \u200ereceive FACT accreditation for adhering to the most stringent cord blood quality standards \u200eset by any internationally recognized, independent accrediting organization. Cryo-Cell has \u200ethe exclusive rights \u200eto PrepaCyte-CB, the industry\u2019s most advanced cord blood processing \u200etechnology.\u200e<\/p>\n
\nCryo-Cell\u2019s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. In February 2021, Cryo-Cell entered into a license agreement with Duke University \u200ethat the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, \u200e\u200evertically \u200eintegrated cellular therapy \u200ecompany. \u200eIn March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. For more information, please visit (www.extravault.com<\/a>).<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release includes \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d) and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). In some cases, you can identify forward-looking statements by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cforecasts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other comparable terminology. Generally, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cplan\u201d and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.<\/p>\n \nWe have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company\u2019s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company\u2019s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company\u2019s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company\u2019s business, the success of the Company\u2019s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company\u2019s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company\u2019s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company\u2019s Form 10-Q filed on October 12, 2023.<\/p>\n \nThis list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20231012909193\/en\/<\/a><\/span><\/p>\n \nIrene Smith KEYWORDS:<\/b> United States North America Florida<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Stem Cells Research<\/p>\n<\/p>\n
\n
813-749-2102
\n
Ismith@cryo-cell.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20231012909193\/en\/1769919\/3\/Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n